Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3B
read at Endpoints ↗DealPositive
Roche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies.
Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 billion overall.
The deal also includes plans to explore the degrader platform in additional areas such as immunology and neurology.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Nurix to work with Roche on BTK degrader in pact worth up to $2.3B”
read at Endpoints ↗88 words · retrieved Jun 8
comments(0)
5-min edit window · permanent after that